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Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart
disease characterized by left ventricular (LV) hypertrophy
due to mutations in 11 genes encoding proteins of the sar-
comere. Whether a primary abnormality of the mitral
valve is part of this disease process is unresolved.
Purpose
We have applied cardiovascular magnetic resonance
(CMR) with its high spatial and temporal resolution, to
characterize mitral valve morphology in a large HCM pop-
ulation.
Methods
Cine CMR images were obtained in 224 HCM subjects (42
± 18 years; 71% male) and 70 normal control subjects (41
± 17 years; 69% male). ECG-gated, breath-hold cines were
obtained in the 3-chamber cine view (3CV) and in contig-
uous 10 mm thick short-axis slices achieving complete
coverage of the LV. Anterior mitral leaflet (AML) and pos-
terior mitral leaflet (PML) lengths were manually meas-
ured at end-diastole in the 3CV when the leaflets were
fully extended parallel to the anterior septum and antero-
lateral wall.
Results
The AML and PML lengths were greater in HCM patients
compared to controls (26 ± 4 mm vs. 20 ± 4 mm; P <
0.001 and 14 ± 4 mm vs. 11 ± 3 mm; P < 0.001, respec-
tively), including 24 (10%) with substantially increased
AML length of ≥32 mm (≥3 SD above control). AML and
PML lengths measured in vivo by CMR did not differ sig-
nificantly from that previously reported valves removed at
surgery or postmortem (p = NS).
Although AML length was longer in male patients (26 ± 4
mm vs. 25 ± 4 mm in females, p = 0.04) there was no dif-
ference with respect to age, so that HCM patients ≤16
years of age had similar leaflet lengths to those ≥65 years
(23 ± 5 mm vs. 26 ± 3 mm; p = 0.05). In addition, there
was no difference in AML length in HCM patients with or
without LV outflow obstruction (27 ± 4 vs. 26 ± 5 mm; p
= 0.10), nor between AML length and maximum LV wall
thickness (R = 0.11; p = 0.09) or total LV mass (R = 0.72;
p = 0.3). Specifically, in HCM patients with only limited
hypertrophy (13-19 mm), 31 patients (14%) had AML
lengths which were greatly increased (≥2 SD above con-
trols).
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CMR provides an accurate in vivo assessment of mitral
valve leaflets lengths, which are increased in HCM
patients, unrelated to other clinical and demographic var-
iables, including age and magnitude of LV hypertrophy.
These findings suggest that in addition to LV hypertrophy,
enlargement of the mitral valve is likely part of the pri-
mary phenotypic expression of HCM.Page 2 of 2
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